IIM
DNLI icon

Ironwood Investment Management’s Denali Therapeutics DNLI Stock Holding History

Ironwood Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
52,080
+18
+0% +$370 0.46% 63
2026
Q1 		$1,000K Buy
52,062
+1,129
+2% +$22.5K 0.42% 74
2025
Q4 		$841K Sell
50,933
-1,853
-4% -$31.3K 0.35% 84
2025
Q3 		$766K Sell
52,786
-426
-0.8% -$6.12K 0.33% 88
2025
Q2 		$744K Buy
53,212
+3,907
+8% +$55K 0.36% 85
2025
Q1 		$670K Buy
49,305
+12,759
+35% +$244K 0.37% 83
2024
Q4 		$745K Sell
36,546
-38
-0.1% -$973 0.37% 83
2024
Q3 		$1.07M Buy
36,584
+355
+1% +$8.8K 0.52% 65
2024
Q2 		$841K Buy
36,229
+165
+0.5% +$3.17K 0.45% 73
2024
Q1 		$740K Buy
36,064
+18,126
+101% +$341K 0.36% 83
2023
Q4 		$385K Sell
17,938
-158
-0.9% -$3.13K 0.2% 112
2023
Q3 		$373K Sell
18,096
-623
-3% -$15.8K 0.23% 104
2023
Q2 		$552K Sell
18,719
-77
-0.4% -$2.17K 0.32% 88
2023
Q1 		$433K Sell
18,796
-353
-2% -$9.71K 0.27% 105
2022
Q4 		$533K Sell
19,149
-759
-4% -$22.6K 0.35% 90
2022
Q3 		$611K Buy
19,908
+52
+0.3% +$1.69K 0.43% 86
2022
Q2 		$584K Buy
19,856
+14
+0.1% +$367 0.39% 90
2022
Q1 		$638K Buy
19,842
+459
+2% +$15.8K 0.35% 99
2021
Q4 		$864K Buy
19,383
+290
+2% +$13.7K 0.43% 79
2021
Q3 		$963K Buy
19,093
+19
+0.1% +$1.07K 0.5% 68
2021
Q2 		$1.5M Sell
19,074
-446
-2% -$27.6K 0.76% 38
2021
Q1 		$1.11M Buy
19,520
+155
+0.8% +$10.4K 0.59% 62
2020
Q4 		$1.62M Sell
19,365
-553
-3% -$33.4K 0.95% 28
2020
Q3 		$714K Sell
19,918
-40
-0.2% -$1.21K 0.51% 78
2020
Q2 		$483K Sell
19,958
-112
-0.6% -$2.63K 0.38% 100
2020
Q1 		$351K Sell
20,070
-741
-4% -$15.5K 0.35% 104
2019
Q4 		$363K Sell
20,811
-1,696
-8% -$28.2K 0.25% 121
2019
Q3 		$345K Sell
22,507
-88
-0.4% -$1.68K 0.26% 119
2019
Q2 		$469K Sell
22,595
-12
-0.1% -$269 0.37% 101
2019
Q1 		$525K Buy
22,607
+12,515
+124% +$262K 0.43% 89
2018
Q4 		$209K Buy
+10,092
New +$183K 0.19% 137

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ironwood Investment Management's DNLI Position: Q2 2026 in Review

Ironwood Investment Management increased its Denali Therapeutics (DNLI) stake by 0.03% in Q2 2026, buying an estimated $370 and bringing the position to 52,080 shares worth $1.34M. The position accounts for 0.46% of the portfolio, ranked #63.

Ironwood Investment Management first reported a position in DNLI in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.62M in Q4 2020. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Ironwood Investment Management held 52,080 shares of Denali Therapeutics worth $1.34M as of Q2 2026.
  • Ironwood Investment Management bought 18 Denali Therapeutics shares in Q2 2026, an estimated $370.
  • Denali Therapeutics made up 0.46% of Ironwood Investment Management's portfolio in Q2 2026, its #63 holding.
  • Ironwood Investment Management first reported a position in Denali Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Ironwood Investment Management's Denali Therapeutics position peaked at $1.62M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Ironwood Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.